Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Completed · Phase 2

Conditions studied: Treatment of Hepatitis C

In brief

Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA \< 6 x106 IU/mL Duration of Subjects will be treated for 8 weeks and followed for 24 weeks post- Treatment: treatment

Key facts

Study ID

NCT02480387

Run by

Peter J. Ruane, M.D., Inc.

People needed

20

Starts

2015-05-01

Expected to finish

2016-01-01

Last updated by the study team

2016-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronic HCV GT1, treatment-naïve, non-cirrhotic adult subjects.
• HCV RNA levels more than 10,000 IU/mL and less than 6,000,000 IU/mL at Screening

You may not qualify if…

• Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug.
• Solid organ transplantation.
• Significant cardiac disease or other significant co-morbidities that could interfere with study treatment.
• Malignancy within the 3 years prior to screening, with the exception of specific cancers that have been cured by surgical resection (basal cell skin cancer, etc.). Subjects under evaluation for possible malignancy are not eligible.
• Infection with hepatitis B virus (HBV)

Where it is running

• Peter J. Ruane, MD, Inc. — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.